Article Text

PDF
AB0266 Responsiveness and minimal important difference of the rheumatoid arthritis-work instability scale (ra-wis)
  1. D. Revicki1,
  2. M. A. Cifaldi2,
  3. S. Safikhani1,
  4. N. Chen2,
  5. A. Ganguli2
  1. 1United Biosource, Bethesda
  2. 2AbbVie Inc., North Chicago, IL, United States

Abstract

Background Within 2 to 3 years of disease, approximately 20 to 30% of patients with early rheumatoid arthritis (RA) become permanently work disabled (Allaire, 2008). Disability-associated ‘work instability’ defined as the mismatch between their functional capabilities and job demands, is a risk factor for loss of employment. The RA-WIS was developed to assess the level of risk for work disability in RA patients; however there is limited information on its responsiveness and minimal important difference (MID).

Objectives The objective of this study was to evaluate the responsiveness and MID of the RA-WIS in patients with early RA.

Methods A secondary analysis was conducted using data from PROWD study, a 56-week, randomized, and controlled trial of patients with early RA (Bejarano, 2008). Clinical measures included American College of Rheumatology (ACR) response and Disease Activity Score-28 (DAS28), and patient-reported outcomes included the RA-WIS and Health Assessment Questionnaire Disability Index (HAQ-DI), which were collected at Baseline and at Weeks 12, 16, 24 and 56. Responsiveness of the RA-WIS was evaluated at Weeks 24 and 56 based on DAS28 (<3.2 vs. >3.2) and ACR response criteria (<20% vs. 20% to <50%;) using analysis of covariance, adjusting for age, gender and baseline RA-WIS scores. MID estimates were derived from these analyses.

Results A total of 148 patients were included in the analysis sample, and was 56% female, with a mean age of 46.8 years. Patients experienced RA symptoms for a mean 8.7 months with mean DAS scores of 5.9 and mean HAQ-DI scores of 1.3. Mean Baseline to Week 24 RA-WIS Total change scores were significantly different among ACR responder groups (P≤0.0001) and between DAS28 remission status groups (P<0.001). There was a -5.3 to -7.7 point RA-WIS score change associated with an improvement of 20% to <50% in ACR from baseline to 24 or 56 weeks. There was a -5.4 to -6.1 point RA-WIS point change associated with a moderate response for DAS28 at 24 or 56 weeks.

Conclusions These findings provide evidence on the responsiveness of the RA-WIS for evaluating work disability in RA patients. The MID for the RA-WIS is estimated at 5 to 7 points.

Disclosure of Interest D. Revicki Consultant for: AbbVie, M. Cifaldi Shareholder of: AbbVie, Employee of: AbbVie. The design, study conduct, and financial support for the study/trial was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract., S. Safikhani Consultant for: AbbVie, N. Chen Shareholder of: AbbVie, Employee of: AbbVie. The design, study conduct, and financial support for the study/trial was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract., A. Ganguli Shareholder of: AbbVie, Employee of: AbbVie. The design, study conduct, and financial support for the study/trial was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.